Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin’s lymphoma

References

• JemalASiegelRWardECancer statistics, 2008CA Cancer J Clin2008582719618287387
   PubMed Web of Science ®Google Scholar
• FisherRIOverview of non-Hodgkin’s lymphoma: biology, staging, and treatmentSemin Oncol2003302 Suppl 43912728402
   PubMed Web of Science ®Google Scholar
• TraweekSTLiuJJohnsonRMWinbergCDRappaportHHigh-grade transformation of chronic lymphocytic leukemia and low-grade non-Hodgkin’s lymphoma. Genotypic confirmation of clonal identityAm J Clin Pathol199310055195268249891
   PubMed Web of Science ®Google Scholar
• ShanDLedbetterJAPressOWApoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodiesBlood1998915164416529473230
   PubMed Web of Science ®Google Scholar
• CraggMSMorganSMChanHTComplement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid raftsBlood200310131045105212393541
   PubMed Web of Science ®Google Scholar
• CartronGDacheuxLSallesGTherapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa geneBlood200299375475811806974
   PubMed Web of Science ®Google Scholar
• BeersSAChanCHJamesSType II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activationBlood2008112104170417718583569
   PubMed Web of Science ®Google Scholar
• ChanHTHughesDFrenchRRCD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane raftsCancer Res200363175480548914500384
   PubMed Web of Science ®Google Scholar
• CraggMSGlennieMJAntibody specificity controls in vivo effector mechanisms of anti-CD20 reagentsBlood200410372738274314551143
   PubMed Web of Science ®Google Scholar
• IvanovAKrysovSCraggMSIllidgeTRadiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosisClin Cancer Res200814154925493418676767
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKlineBexxar (Tositumomab and Iodine 131I Tositumomab): Prescribing Information102005133http://www.bexxar.com/Accessed July 27, 2009.
   Google Scholar
• SilbersteinEBAlaviABalonHRDVBSociety of Nuclear Medicine Procedure Guideline for Therapy of Thyroid Disease with Iodine-131 (Sodium Iodide) version 2.099200518http://interactive.snm.org/index.cfm?PageID=772&RPID=969Accessed July 27, 2009.
   Google Scholar
• DavisTAKaminskiMSLeonardJPThe radioisotope contributes significantly to the activity of radioimmunotherapyClin Cancer Res200410237792779815585610
   PubMed Web of Science ®Google Scholar
• Feuring-BuskeMKnebaMUnterhaltMIDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study GroupAnn Hematol200079949350011043420
   PubMed Web of Science ®Google Scholar
• MaloneyDGGrillo-LopezAJWhiteCAIDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphomaBlood1997906218821959310469
   PubMed Web of Science ®Google Scholar
• McLaughlinPGrillo-LopezAJLinkBKRituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment programJ Clin Oncol1998168282528339704735
   PubMed Web of Science ®Google Scholar
• TurnerJHMartindaleAABoucekJClaringboldPGLeahyMF131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospitalCancer Biother Radiopharm200318451352414503945
   PubMed Web of Science ®Google Scholar
• LeahyMFSeymourJFHicksRJTurnerJHMulticenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin’s lymphomaJ Clin Oncol200624274418442516940276
   PubMed Web of Science ®Google Scholar
• VoseJMWahlRLSalehMMulticenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomasJ Clin Oncol20001861316132310715303
   PubMed Web of Science ®Google Scholar
• DaviesAJRohatinerAZHowellSTositumomab and iodine 131I tositumomab for recurrent indolent and transformed B-cell non-Hodgkin’s lymphomaJ Clin Oncol20042281469147915084620
   PubMed Web of Science ®Google Scholar
• MonesJVColemanMKostakogluLDose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin’s lymphoma (NHL) and extensive bone marrow involvementLeuk Lymphoma200748234234817325895
   PubMed Web of Science ®Google Scholar
• KaminskiMSZasadnyKRFrancisIRRadioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibodyN Engl J Med199332974594657687326
   PubMed Web of Science ®Google Scholar
• SgourosGSqueriSBallangrudAMPatient-specific, 3-dimensional dosimetry in non-Hodgkin’s lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-responseJ Nucl Med200344226026812571219
   PubMed Web of Science ®Google Scholar
• KaminskiMSZasadnyKRFrancisIRIodine-131-anti-B1 radioimmunotherapy for B-cell lymphomaJ Clin Oncol1996147197419818683227
   PubMed Web of Science ®Google Scholar
• KaminskiMSEstesJZasadnyKRRadioimmunotherapy with iodine (131I) tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experienceBlood20009641259126610942366
   PubMed Web of Science ®Google Scholar
• KaminskiMSZelenetzADPressOWPivotal study of iodine 131I tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomasJ Clin Oncol200119193918392811579112
   PubMed Web of Science ®Google Scholar
• KaminskiMSTuckMEstesJ131I-tositumomab therapy as initial treatment for follicular lymphomaN Engl J Med2005352544144915689582
   PubMed Web of Science ®Google Scholar
• NordoyTKolstadATuckMKAabergeISHusebekkAKaminskiMSRadioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin’s B-cell lymphoma does not induce loss of acquired humoral immunity against common antigensClin Immunol20011001404811414744
   PubMed Web of Science ®Google Scholar
• BennettJMKaminskiMSLeonardJPAssessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine 131I tositumomabBlood2005105124576458215731177
   PubMed Web of Science ®Google Scholar
• KaminskiMSEstesJTuckMRossCWWahlRL131I-tositumomab monotherapy as frontline treatment for follicular lymphoma: Updated results after a median follow-up of 8 yearsJ Clin Oncol20078033
   Google Scholar
• HorningSJYounesAJainVEfficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximabJ Clin Oncol200523471271915613695
   PubMed Web of Science ®Google Scholar
• FisherRIKaminskiMSWahlRLTositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin’s lymphomasJ Clin Oncol200523307565757316186600
   PubMed Web of Science ®Google Scholar
• KaminskiMSRadfordJAGregorySARe-treatment with I-131 tositumomab in patients with non-Hodgkin’s lymphoma who had previously responded to I-131 tositumomabJ Clin Oncol200523317985799316204016
   PubMed Web of Science ®Google Scholar
• DosikADColemanMKostakogluLSubsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphomaCancer2006106361662216362977
   PubMed Web of Science ®Google Scholar
• PressOWEaryJFAppelbaumFRRadiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow supportN Engl J Med199332917121912247692295
   PubMed Web of Science ®Google Scholar
• PressOWEaryJFAppelbaumFRPhase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomasLancet199534689713363407623531
   PubMed Web of Science ®Google Scholar
• LiuSYEaryJFPetersdorfSHFollow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescueJ Clin Oncol19981610327032789779701
   PubMed Web of Science ®Google Scholar
• PressOWEaryJFGooleyTA phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomasBlood20009692934294211049969
   PubMed Web of Science ®Google Scholar
• GopalAKGooleyTAMaloneyDGHigh-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysisBlood200310272351235712750161
   PubMed Web of Science ®Google Scholar
• GopalAKRajendranJGPetersdorfSHHigh-dose chemoradioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphomaBlood20029993158316211964278
   PubMed Web of Science ®Google Scholar
• GopalAKRajendranJGGooleyTAHigh-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults ≥60 years old with relapsed or refractory B-cell lymphomaJ Clin Oncol200725111396140217312330
   PubMed Web of Science ®Google Scholar
• VoseJMBiermanPJEnkeCPhase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin’s lymphomaJ Clin Oncol200523346146715534357
   PubMed Web of Science ®Google Scholar
• PressOWUngerJMBrazielRMPhase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911J Clin Oncol200624254143414916896003
   PubMed Web of Science ®Google Scholar
• LeonardJPColemanMKostakogluLAbbreviated chemotherapy with fludarabine followed by tositumomab and iodine 131I tositumomab for untreated follicular lymphomaJ Clin Oncol200523245696570416110029
   PubMed Web of Science ®Google Scholar
• LinkBKaminiskiMSColemanMLeonardJPPhase II study of CVP followed by tositumomab and iodine 131I tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin’s lymphoma (NHL)J Clin Oncol(Meeting Abstracts)2004226520
   Web of Science ®Google Scholar
• GopalAKPressOWWilburSMMaloneyDGPagelJMRituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 AbBlood2008112383083518502830
   PubMed Web of Science ®Google Scholar
• ChesonBDPfistnerBJuweidMERevised response criteria for malignant lymphomaJ Clin Oncol200725557958617242396
   PubMed Web of Science ®Google Scholar
• TorizukaTZasadnyKRKisonPVRommelfangerSGKaminskiMSWahlRLMetabolic response of non-Hodgkin’s lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PETJ Nucl Med2000416999100510855624
   PubMed Web of Science ®Google Scholar
• JaceneHAFiliceRKasecampWWahlRL18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapyJ Nucl Med200950181719091903
   PubMed Web of Science ®Google Scholar
• TsujimotoYFingerLRYunisJNowellPCCroceCMCloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocationScience19842264678109710996093263
   PubMed Web of Science ®Google Scholar
• CoiffierBLepageEBriereJCHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphomaN Engl J Med2002346423524211807147
   PubMed Web of Science ®Google Scholar
• GarberKUsers fear that lymphoma drugs will disappearJ Natl Cancer Inst200799749849950117405990
   PubMedGoogle Scholar
• HochsterHWellerEGascoyneRDMaintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 StudyJ Clin Oncol200927101607161419255334
   PubMed Web of Science ®Google Scholar
• HagenbeekAMaintenance or eradication of residual disease in indolent lymphoma: where do we stand?J Clin Oncol200927101540154219255319
   PubMed Web of Science ®Google Scholar
• PlastarasJPGlatsteinESchusterSJCommentary: let the tail wag the dog: the case for radioimmunotherapy of low-grade follicular lymphomaOncologist200813665565618586920
   PubMed Web of Science ®Google Scholar